BRCA2 and prostate cancer: In the metastatic setting, the Prostate Cancer Foundation-Stand Up To Cancer (SU2C-PCF) team identified a high proportion of actionable mutations, including 23% with mutations and other alterations in DDR genes, such as BRCA2 (13%), ATM (7.3%), and BRCA1 (0.3%), along with mutations in MMR genes, such as MSH2 (2%) [50].